Precigen, Inc. (PGEN)
4.52
-0.14
(-3.00%)
USD |
NASDAQ |
Nov 13, 16:00
4.52
0.00 (0.00%)
After-Hours: 19:59
Precigen Enterprise Value : 1.723B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.723B |
| November 11, 2026 | 1.745B |
| November 10, 2026 | 1.673B |
| November 09, 2026 | 1.748B |
| November 06, 2026 | 1.655B |
| November 05, 2026 | 1.566B |
| November 04, 2026 | 1.865B |
| November 03, 2026 | 1.935B |
| November 02, 2026 | 1.895B |
| October 30, 2026 | 2.541B |
| October 29, 2026 | 2.433B |
| October 28, 2026 | 2.232B |
| October 27, 2026 | 2.258B |
| October 26, 2026 | 2.218B |
| October 23, 2026 | 2.272B |
| October 22, 2026 | 2.344B |
| October 21, 2026 | 2.419B |
| October 20, 2026 | 2.501B |
| October 19, 2026 | 2.440B |
| October 16, 2026 | 2.342B |
| October 15, 2026 | 2.632B |
| October 14, 2026 | 2.690B |
| October 13, 2026 | 2.734B |
| October 12, 2026 | 2.799B |
| October 09, 2026 | 2.853B |
| Date | Value |
|---|---|
| October 08, 2026 | 2.777B |
| October 07, 2026 | 2.756B |
| October 06, 2026 | 2.760B |
| October 05, 2026 | 2.828B |
| October 02, 2026 | 3.114B |
| October 01, 2026 | 2.996B |
| September 30, 2026 | 3.122B |
| September 29, 2026 | 2.942B |
| September 28, 2026 | 2.856B |
| September 25, 2026 | 2.835B |
| September 24, 2026 | 2.817B |
| September 23, 2026 | 2.724B |
| September 22, 2026 | 2.885B |
| September 21, 2026 | 2.817B |
| September 18, 2026 | 2.845B |
| September 17, 2026 | 2.878B |
| September 16, 2026 | 2.722B |
| September 15, 2026 | 2.566B |
| September 14, 2026 | 2.512B |
| September 11, 2026 | 2.512B |
| September 10, 2026 | 2.452B |
| September 09, 2026 | 2.495B |
| September 08, 2026 | 2.520B |
| September 04, 2026 | 2.602B |
| September 03, 2026 | 2.616B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 166.16M |
| Aldeyra Therapeutics, Inc. | -2.486M |
| Repligen Corp. | 9.268B |
| AC Immune SA | 111.10M |
| Inovio Pharmaceuticals, Inc. | 119.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 35.77M |
| Revenue (Quarterly) | 74.15M |
| Total Expenses (Quarterly) | 38.38M |
| EPS Diluted (Quarterly) | 0.0849 |
| Gross Profit Margin (Quarterly) | 90.79% |
| Profit Margin (Quarterly) | 48.24% |
| Earnings Yield | 0.99% |
| Operating Earnings Yield | 1.93% |
| Normalized Earnings Yield | 0.9867 |